A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer

Summary

The goal of this clinical trial is to investigate the BST02, a tumor infiltrating lymphocyte product, collected from the locally advanced liver cancer subjects The main questions it aims to answer are: 1. Safety and tolerability of BST02. 2. Preliminary efficacy of BST02. Participants will receive a cytoreductive surgery to collect samples for the manufacture of BST02. Participants will receive BST02 infusion followed by IL-2 infusion. Blood samples will be collected for the analysis of PK and safety.

Timeline

Start

2024-07-04

Primary completion

2025-07-03

Completion

2025-12-03

Drugs

Indications